BACKGROUND: There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast cancer (MBC). METHODS: The study included 198 MBC patients (96 with and 102 without BM). Using tissue microarrays derived from the primary tumor, we assessed by immunohistochemical expression of ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, and claudin 3 and 4. RESULTS: Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001), cytoplasmic expression of Rad51 (HR 1.87; P = 0.014) and ER-negativity (HR 1.72; P = 0.029) were associated with increased risk of BM in the multivariate analysis. A three-biomarker profile including ER, Ki-67 and Rad51 vs. other subtypes combined yielded an HR of 4.43 (P < 0.001). CONCLUSIONS: ER-negativity, cytoplasmic expression of Rad51 and high Ki-67 are associated with increased risk of BM.
BACKGROUND: There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast cancer (MBC). METHODS: The study included 198 MBCpatients (96 with and 102 without BM). Using tissue microarrays derived from the primary tumor, we assessed by immunohistochemical expression of ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, and claudin 3 and 4. RESULTS: Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001), cytoplasmic expression of Rad51 (HR 1.87; P = 0.014) and ER-negativity (HR 1.72; P = 0.029) were associated with increased risk of BM in the multivariate analysis. A three-biomarker profile including ER, Ki-67 and Rad51 vs. other subtypes combined yielded an HR of 4.43 (P < 0.001). CONCLUSIONS: ER-negativity, cytoplasmic expression of Rad51 and high Ki-67 are associated with increased risk of BM.
Authors: Sophia B Chernikova; Rochelle B Nguyen; Jessica T Truong; Stephano S Mello; Jason H Stafford; Michael P Hay; Andrew Olson; David E Solow-Cordero; Douglas J Wood; Solomon Henry; Rie von Eyben; Lei Deng; Melanie Hayden Gephart; Asaithamby Aroumougame; Claudia Wiese; John C Game; Balázs Győrffy; J Martin Brown Journal: J Clin Invest Date: 2018-10-29 Impact factor: 14.808
Authors: Renata Duchnowska; Jacek Jassem; Chirayu Pankaj Goswami; Murat Dundar; Yesim Gökmen-Polar; Lang Li; Stephan Woditschka; Wojciech Biernat; Katarzyna Sosińska-Mielcarek; Bogumiła Czartoryska-Arłukowicz; Barbara Radecka; Zorica Tomasevic; Piotr Stępniak; Konrad Wojdan; George W Sledge; Patricia S Steeg; Sunil Badve Journal: J Neurooncol Date: 2015-01-06 Impact factor: 4.130
Authors: Adrian P Wiegmans; Fares Al-Ejeh; Nicole Chee; Pei-Yi Yap; Julia J Gorski; Leonard Da Silva; Emma Bolderson; Georgia Chenevix-Trench; Robin Anderson; Peter T Simpson; Sunil R Lakhani; Kum Kum Khanna Journal: Oncotarget Date: 2014-05-30